Sunhawk Vision announced the results of its phase-2 trial for dry eye disease were published in a top tier peer-reviewed journal, Clinical Therapeutics.
This first-in-class anti-miRNA-328 therapy (called SHJ002) showed significant efficacy in improving signs (corneal repair (P=0.001)) and multiple symptoms with no treatment-related adverse events. This revolutionized therapeutic approach disrupts the current DED treatment landscape which heavily relies on anti-inflammation or tear production.
SHJ002 possesses a potential game-changer.

Link：https://pubmed.ncbi.nlm.nih.gov/42036272/